Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less radiation for breast cancer? a trial tests a smarter, response-based approach

NCT ID NCT07724769

Disease control Sponsor: Aya Ahmed Sayed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial is investigating whether women with node-positive breast cancer whose lymph nodes are cancer-free after chemotherapy can safely receive less extensive radiation. Instead of radiating the entire lymph node region, the study compares standard radiation to a more targeted approach. The goal is to maintain a low risk of cancer recurrence while reducing side effects from treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
adjuvant radiotherapy (radiation therapy to the breast or chest wall, with or without regional lymph nodes)
What this could lead to
If successful, this approach could allow many breast cancer patients to avoid unnecessary radiation to the lymph nodes, reducing side effects without increasing the risk of cancer returning.
What could go wrong
This is a relatively small, early-stage study. It is not yet known whether reducing radiation will lead to higher recurrence rates in the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients \>= 18 years old. * Histologically confirmed invasive breast cancer, cT1-3 N1M0 according to the 8th AJCC edition. * Biopsy-proven cN1 disease at diagnosis. * Completion of standard neoadjuvant systemic therapy. * Surgical treatment of breast and axilla. * Pathologically confirmed ypN0 status. * ECOG performance status 0-2. * Suitable for adjuvant radiotherapy. * Signed informed consent. Exclusion Criteria: * Metastatic disease (M1). * Prior thoracic irradiation. * Pregnancy or lactation. * Severe uncontrolled comorbid illness. * Any contraindication to radiotherapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.